Status:
COMPLETED
Reward Mechanisms in Obesity
Lead Sponsor:
Zoltan Pataky
Collaborating Sponsors:
University of Geneva, Switzerland
Conditions:
Obesity
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The study aims to investigate the effects of 3.0 mg of liraglutide on reward brain circuits in human obesity and to better understand its effects on weight loss (in patients without diabetes). Accord...
Eligibility Criteria
Inclusion
- BMI ≥ 30 kg/m2 and \< 40 kg/m2
- right-handed
- current non-smokers
- with stable body weight (\<5% reported change during the previous 3 months)
Exclusion
- History of any psychiatric, neurological, cardiovascular, renal or liver disease, malignancies, type 1 and type 2 diabetes mellitus
- use of centrally acting medication, glucocorticoides, insulin, orlistat
- any substance abuse
- food allergies
- deficits of smell and taste
- history of pancreatitis
- family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma
- pregnancy
- contraindications for fMRI
Key Trial Info
Start Date :
March 5 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2020
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03347890
Start Date
March 5 2018
End Date
March 30 2020
Last Update
April 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals of Geneva
Geneva, Switzerland, 1206